HC Wainwright Has Optimistic Outlook of SAGE Q1 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - HC Wainwright boosted their Q1 2025 earnings per share estimates for Sage Therapeutics in a note issued to investors on Wednesday, February 12th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($1.11) per share for the quarter, up from their previous estimate of ($1.54). HC Wainwright currently has a "Neutral" rating and a $12.00 target price on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Sage Therapeutics' Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.14) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.86) EPS, FY2028 earnings at ($2.63) EPS and FY2029 earnings at ($1.84) EPS.

A number of other analysts also recently weighed in on the company. StockNews.com downgraded Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. Royal Bank of Canada upgraded shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price objective on the stock in a research note on Thursday, November 21st. Stifel Nicolaus decreased their target price on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a report on Monday, December 16th. Wedbush reaffirmed a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Piper Sandler decreased their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating on the stock in a research note on Thursday, January 2nd. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Sage Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $9.65.

Sage Therapeutics Stock Performance

Shares of SAGE stock traded up $0.11 during trading on Monday, hitting $7.15. The company had a trading volume of 2,179,837 shares, compared to its average volume of 2,379,527. The stock's 50-day moving average price is $6.49 and its 200 day moving average price is $6.82. Sage Therapeutics has a one year low of $4.62 and a one year high of $23.22. The firm has a market capitalization of $439.58 million, a P/E ratio of -1.08 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%.

Hedge Funds Weigh In On Sage Therapeutics

Hedge funds have recently made changes to their positions in the stock. US Bancorp DE increased its position in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 2,268 shares during the period. Teacher Retirement System of Texas increased its position in shares of Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after buying an additional 2,446 shares during the period. Picton Mahoney Asset Management increased its position in shares of Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 3,581 shares during the period. Geode Capital Management LLC raised its stake in Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after buying an additional 3,757 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Sage Therapeutics by 31.2% during the fourth quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock valued at $99,000 after acquiring an additional 4,350 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.